sFGL2 as a Potential Immunosuppressive Biomarker Associated With COVID‐19 Severity in Kidney Transplant Recipients
sFGL2 was associated with immunosuppression, disease severity, and prognosis in KTRs with COVID-19, suggesting that it could serve as a novel biomarker for monitoring immune status.
Authors
- Yingzi Ming (ORCID: https://orcid.org/0000-0002-3004-4405)
- Jiang Zhu (ORCID: https://orcid.org/0000-0002-6860-8739)
- Bo Peng (ORCID: https://orcid.org/0000-0003-4482-2885)
- Yufei Zhang (ORCID: https://orcid.org/0009-0008-8723-1683)
- Kai Liu (ORCID: https://orcid.org/0000-0003-3633-1226)
- Peng Ding (ORCID: https://orcid.org/0009-0006-6683-2231)
- Min Yang (ORCID: https://orcid.org/0000-0001-8366-087X)
- Tianyin Wang (ORCID: https://orcid.org/0000-0002-0208-1794)
Institutions
- Central South University (CN)
- Translational Research in Oncology (FR)
- Third Xiangya Hospital (CN)
Publication Details
- Journal
- Immunity Inflammation and Disease
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1002/iid3.70296
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China